Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.
Performance of anti-pseudomonal beta lactams on the Accelerate PhenoTest® BC kit against a collection of P. aeruginosa isolates
Journal of Clinical Microbiology
Aaron Sikorski , Alena Shamsheyeva, Dulini Gamage, Niels Oppermann, Amira Bhalodi, Romney Humphries (Accelerate Diagnostics, Inc.)
Performance of the BioCheck SARS-CoV-2 IgM and IgG Antibody Tests in Clinical Specimens from China and the United States
Elise Blackmore, Shelley Campeau, Jiao Wei, Evelin Logis, and Joanna Ip (Accelerate Diagnostics, Inc. (Tucson, AZ); Sophonix Co. Ltd (Beijing, China); BioCheck, Inc. (San Francisco, CA))
Clinical Performance and Impact of Accelerate Pheno for Gram-negative Bacteremia in Hospitalized Children
Michelle Lee, Tonya Scardina, Xiaotian Zheng, Sameer J Patel (Ann & Robert H. Lurie Children’s Hospital of Chicago)
Pharmacist-driven Implementation of Fast Identification and Antimicrobial Susceptibility Testing Improves Outcomes for Patients with Gram-negative Bacteremia and Candidemia
Antimicrobial Agents and Chemotherapy
Sahil Sheth, Michael Miller, Angela Beth Prouse, and Scott Baker (Peninsula Regional Medical Center)
Clinical Impact of Accelerate Pheno™ Rapid Blood Culture Detection System in Bacteremic Patients
Clinical Infectious Diseases
R K Dare, K Lusardi, C Pearson, K D McCain, B Daniels, S Van, J C Rico, J Painter, M Lakkad, E R Rosenbaum, J R Bariola (University of Arkansas for Medical Sciences)
Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram Negative Bacteremia (RAPIDS-GN)
Clinical Infectious Diseases
Banerjee R, Komarow L, Virk A, et al. (Antibacterial Resistance Leadership Group (ARLG))
Performance of the Accelerate Pheno system in a tertiary care hospital in Germany
Benjamin Berinson, Flaminia Olearo, Anna Both, et al. (University Medical Center Hamburg-Eppendorf)
Comparison of the Accelerate Pheno rapid diagnostic system with standard of care for diagnosing Gram-negative bloodstream infections: bacterial identification, antimicrobial sensitivity and turnaround time
Luke Blagdon Snell, Jasper Vink, Lyndsay Rowley, et al. (Guy's and St Thomas' NHS Foundation Trust, King's College London, St George's Hospital)
Evaluation of antimicrobial susceptibility testing assays for ceftazidime-avibactam and ceftolozane-tazobactam with Gram-negative bacteria directly from positive blood culture on the Accelerate Pheno system
Niels Oppermann, Anyangatia Ndobegang, Aaron Sikorski, et al. (Accelerate Diagnostics)